OTCPK:PLHN.F

Stock Analysis Report

Executive Summary

Paul Hartmann AG manufactures and sells medical and hygiene products for wound care, incontinence, disinfection, and surgical efficiency in Europe, North and South America, Africa, Asia, and Oceania.

Snowflake

Flawless balance sheet average dividend payer.


Similar Companies

Share Price & News

How has Paul Hartmann's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PLHN.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

PLHN.F

2.4%

US Medical Equipment

0.9%

US Market


1 Year Return

n/a

PLHN.F

23.9%

US Medical Equipment

16.8%

US Market

Return vs Industry: Insufficient data to determine how PLHN.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how PLHN.F performed against the US Market.


Shareholder returns

PLHN.FIndustryMarket
7 Day0%2.4%0.9%
30 Day0%3.6%4.5%
90 Day1.6%2.2%6.2%
1 Yearn/a25.0%23.9%19.4%16.8%
3 Yearn/a90.3%84.5%47.5%38.0%
5 Year-17.6%-17.6%117.4%93.9%62.0%44.1%

Price Volatility Vs. Market

How volatile is Paul Hartmann's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Paul Hartmann undervalued compared to its fair value and its price relative to the market?

14.46x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: PLHN.F ($331.32) is trading above our estimate of fair value ($196.52)

Significantly Below Fair Value: PLHN.F is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PLHN.F is good value based on its PE Ratio (14.5x) compared to the Medical Equipment industry average (46.3x).

PE vs Market: PLHN.F is good value based on its PE Ratio (14.5x) compared to the US market (18.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PLHN.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PLHN.F is good value based on its PB Ratio (1.2x) compared to the US Medical Equipment industry average (4x).


Next Steps

Future Growth

How is Paul Hartmann forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Paul Hartmann has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine whether Paul Hartmann is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Paul Hartmann's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Paul Hartmann performed over the past 5 years?

2.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PLHN.F has high quality earnings.

Growing Profit Margin: PLHN.F's current net profit margins (3.4%) are lower than last year (4%).


Past Earnings Growth Analysis

Earnings Trend: PLHN.F's earnings have grown by 2.7% per year over the past 5 years.

Accelerating Growth: PLHN.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PLHN.F had negative earnings growth (-12.8%) over the past year, making it difficult to compare to the Medical Equipment industry average (28.3%).


Return on Equity

High ROE: PLHN.F's Return on Equity (8.7%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Paul Hartmann's financial position?


Financial Position Analysis

Short Term Liabilities: PLHN.F's short term assets (€867.6M) exceeds its short term liabilities (€400.7M)

Long Term Liabilities: PLHN.F's short term assets (€867.6M) exceeds its long term liabilities (301.6M)


Debt to Equity History and Analysis

Debt Level: PLHN.F's debt to equity ratio (11.9%) is considered satisfactory.

Reducing Debt: PLHN.F's debt to equity ratio has reduced from 21.6% to 11.9% over the past 5 years.

Debt Coverage: PLHN.F's debt is well covered by operating cash flow (130.2%).

Interest Coverage: PLHN.F's interest payments on its debt are well covered by EBIT (68x coverage).


Balance Sheet

Inventory Level: PLHN.F has a high level of physical assets or inventory.

Debt Coverage by Assets: PLHN.F's debt is covered by short term assets (assets are 8.1x debt).


Next Steps

Dividend

What is Paul Hartmann's current dividend yield, its reliability and sustainability?

2.33%

Current Dividend Yield


Dividend Yield vs Market

company2.3%marketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: PLHN.F's dividend (2.33%) is higher than the bottom 25% of dividend payers in the US market (1.43%).

High Dividend: PLHN.F's dividend (2.33%) is low compared to the top 25% of dividend payers in the US market (3.68%).


Stability and Growth of Payments

Stable Dividend: PLHN.F's dividends per share have been stable in the past 10 years.

Growing Dividend: PLHN.F's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (33.7%), PLHN.F's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of Paul Hartmann's salary, the management and board of directors tenure and is there insider trading?

8.8yrs

Average management tenure


CEO

Britta Fuenfstueck 0

0.8yrs

Tenure

0

Ms. Britta Fuenfstueck has been Chief Executive Officer at Paul Hartmann AG since January 1, 2019 and its Management Board since January 1, 2019. Ms. Fuenfstueck served as Chairman of the Management Board  ...


Management Age and Tenure

8.8yrs

Average Tenure

Experienced Management: PLHN.F's management team is seasoned and experienced (8.8 years average tenure).


Board Age and Tenure

11.6yrs

Average Tenure

Experienced Board: PLHN.F's board of directors are seasoned and experienced ( 11.6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Stephan Schulz (54yo)

    CFO, Labor Director & Member of the Management Board

    • Tenure: 10.5yrs
  • Raymund Heinen

    Chief Process Officer & Member of the Management Board

    • Tenure: 4.1yrs
  • Michel Kuehn (65yo)

    Chief Commercial Officer of Hygiene & Member of Management Board

    • Tenure: 11.1yrs
  • Michael Banz

    Vice President of Corporate Legal

    • Tenure: 0yrs
  • Ralf Fenske

    Senior Vice President of Corporate Accounting

    • Tenure: 0yrs
  • Peter Halbauer

    Head of Group Purchasing Management

    • Tenure: 11.8yrs
  • Gabriele Müller

    Vice President of Human Resources Management

    • Tenure: 8.8yrs
  • Michael Brauner

    Executive Managing Director of SANIMED Group Germany

    • Tenure: 6.2yrs
  • Christian Sievert

    Senior Vice President Business Unit Risk Prevention

    • Tenure: 0yrs
  • Britta Fuenfstueck

    CEO & Member of Management Board

    • Tenure: 0.8yrs

Board Members

  • Joachim Schielke (70yo)

    Member of Supervisory Board

    • Tenure: 11.6yrs
    • Compensation: €22.50k
  • Fritz-Jürgen Heckmann

    Chairman of Supervisory Board

    • Tenure: 14.3yrs
    • Compensation: €69.50k
  • Werner Casper

    Member of Supervisory Board

    • Tenure: 0yrs
    • Compensation: €22.50k
  • Eduard Schleicher

    Member of Supervisory Board

    • Tenure: 11.6yrs
    • Compensation: €53.83k
  • Gerhard Hirth

    Member of Supervisory Board

    • Tenure: 11.6yrs
    • Compensation: €22.50k
  • Rinaldo Riguzzi (73yo)

    Member of Supervisory Board

    • Tenure: 6.3yrs
  • Christine Geppert

    Member of Supervisory Board

    • Tenure: 0yrs
    • Compensation: €22.50k
  • Wolfgang Röhrl

    Vice President Operations Management Medical Production & Member of Supervisory Board

    • Tenure: 1.8yrs
  • Ralf Willeck

    Deputy Chairman of the Supervisory Board

    • Tenure: 0yrs
  • Yvonne Brix

    Member of Supervisory Board

    • Tenure: 6.5yrs

Company Information

Paul Hartmann AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Paul Hartmann AG
  • Ticker: PLHN.F
  • Exchange: OTCPK
  • Founded: 1818
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: €1.066b
  • Listing Market Cap: €1.179b
  • Shares outstanding: 3.55m
  • Website: https://hartmann.info

Number of Employees


Location

  • Paul Hartmann AG
  • Paul-Hartmann-Strasse 12
  • Heidenheim
  • Baden-Württemberg
  • 89522
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PHH2DB (Deutsche Boerse AG)YesCommon SharesDEEURJan 1992
PLHN.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJan 1992

Biography

Paul Hartmann AG manufactures and sells medical and hygiene products for wound care, incontinence, disinfection, and surgical efficiency in Europe, North and South America, Africa, Asia, and Oceania. The c ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/20 23:59
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.